ValuEngine downgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a hold rating to a sell rating in a research note published on Monday morning.
Other equities analysts have also recently issued research reports about the stock. Cantor Fitzgerald set a $74.00 price objective on shares of ANI Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, October 3rd. Canaccord Genuity set a $75.00 price objective on shares of ANI Pharmaceuticals and gave the company a buy rating in a research note on Thursday, August 16th. BidaskClub upgraded shares of ANI Pharmaceuticals from a hold rating to a buy rating in a research note on Wednesday, June 13th. Finally, Zacks Investment Research cut shares of ANI Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, July 10th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company. ANI Pharmaceuticals currently has an average rating of Hold and an average target price of $72.67.
Shares of ANIP stock opened at $54.38 on Monday. ANI Pharmaceuticals has a 52-week low of $49.76 and a 52-week high of $74.70. The firm has a market capitalization of $668.70 million, a PE ratio of 15.17 and a beta of 2.62. The company has a quick ratio of 2.89, a current ratio of 3.84 and a debt-to-equity ratio of 1.08.
ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.34 by ($0.21). ANI Pharmaceuticals had a net margin of 0.06% and a return on equity of 27.76%. The business had revenue of $47.27 million during the quarter, compared to analyst estimates of $50.70 million. As a group, equities research analysts forecast that ANI Pharmaceuticals will post 4.49 earnings per share for the current year.
Hedge funds have recently made changes to their positions in the company. Mount Yale Investment Advisors LLC acquired a new position in shares of ANI Pharmaceuticals in the 1st quarter valued at $102,000. Sei Investments Co. grew its holdings in shares of ANI Pharmaceuticals by 56.9% in the 1st quarter. Sei Investments Co. now owns 2,252 shares of the specialty pharmaceutical company’s stock worth $131,000 after purchasing an additional 817 shares during the last quarter. Piedmont Investment Advisors LLC bought a new stake in shares of ANI Pharmaceuticals in the 2nd quarter worth about $140,000. Stifel Financial Corp bought a new stake in shares of ANI Pharmaceuticals in the 1st quarter worth about $215,000. Finally, Crossmark Global Holdings Inc. bought a new stake in shares of ANI Pharmaceuticals in the 2nd quarter worth about $235,000. Institutional investors own 60.67% of the company’s stock.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.
Featured Story: Google Finance
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.